16066-97-0

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-Methyl-2-nitropropyl)phenol is used as an intermediate in the synthesis of beta adrenoceptor modulators. These modulators play a crucial role in regulating the activity of beta adrenoceptors, which are involved in various physiological processes, including heart rate, blood pressure, and metabolism.
Additionally, 4-(2-Methyl-2-nitropropyl)phenol is used as a norepinephrine-serotonin uptake inhibitor. This application is particularly relevant for the treatment of obesity, as it helps to regulate the levels of norepinephrine and serotonin in the brain, which are neurotransmitters that influence appetite and mood. By inhibiting their reuptake, 4-(2-Methyl-2-nitropropyl)phenol can potentially contribute to weight loss and improved mood regulation in patients suffering from obesity.

Upstream product

• 79-46-9 2-nitropropane 
• 103-87-7 4-((dimethylamino)methyl)phenol 
• 623-05-2 (4-hydroxyphenyl)methanol 
• 123-08-0 4-hydroxy-benzaldehyde 

Downstream Products

• 85628-47-3 4-Methoxy-(2-methyl-2-nitropropyl)benzol 
• 204592-25-6 Ethyl-(4-[2-methyl-2-nitropropyl]phenoxy)acetate 
• 56490-93-8 1,1-dimethyl-2-(4-methoxyphenyl)ethylamine hydrochloride 
• 869477-96-3 Olodaterol hydrochloride 
• 926319-48-4 6-(phenylmethoxy)-8-[(1R)-1-hydroxy-2-[[2-(4-methoxyphenyl)-1,1-dimethylethyl]amino]ethyl]-2H-1,4-benzoxazin-3(4H)-one hydrochloride 
• 1426954-81-5 1-butoxy-4-(2-methyl-2-nitropropyl)benzene 
• 1401436-45-0 4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-N-(1-(4-methoxyphenyl)-2-methylpropan-2-yl)-6-morpholino-1,3,5-triazin-2-amine 
• 85628-62-2 3,5-Dichlor-4-methoxy-(2-amino-2-methylpropyl)benzol 
• 85628-60-0 3-Chlor-4-methoxy-(2-amino-2-methylpropyl)benzol 
• 85628-51-9 3,5-Dichlor-4-methoxy-(2-methyl-2-nitropropyl)benzol 
• 85628-52-0 3-Chlor-4-methoxy-(2-methyl-2-nitropropyl)benzol 
• 85628-57-5 2,6-Dichlor-4-(2-amino-2-methylpropyl)phenol 
• 85628-56-4 2-Chlor-4-(2-amino-2-methylpropyl)phenol 
• 87664-78-6 2-Methyl-4-(2-amino-2-methylpropyl)phenol 

Relevant academic research and scientific papers

Combination of a beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor for the treatment of obesity

We report the novel combination of a selective beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor (sibutramine) with potential for the treatment of obesity. The synthesis and characterization of 6-[4-[2-[[(2S)-3-(9H-carbazol-4-ylo

SALTS OF BENZOTHIAZOLONE COMPOUND AS BETA-2-ADRENOCEPTOR AGONIST

The present invention provides a compound of formula (I) in acetate salt form (I) a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents a

BENZOTHIAZOLONE COMPOUND

The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form(I) a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination o

BENZOTHIAZOLONE COMPOUND

The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of p

(ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES

Provided herein are (alpha-substituted aralkylamino or heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula 1, and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases

Methods and compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Potent benzimidazolone based human β3-adrenergic receptor agonists

The synthesis and biological evaluation of a series of benzimidazolone β3 adrenergic receptor agonists are described. A trend toward the reduction of rat atrial tachycardia upon increasing steric bulk at the 3-position of the benzimidazolone mo

Aryloxy propanolamines for improving livestock production

Disclosed is a compound represented by structural formula (I): R1 is a substituted or unsubstituted aryl group. R2 and R3 are independently —H, a C1-C4 straight chained or branched alkyl group. R4 and R5 are independently —H, a C1-C4 straight chained or b

Indazolyloxy propanolamines for improving livestock production

Disclosed is compound represented by Structural Formula (I), wherein Ring A, Ring B and Ring C are independently substituted or unsubstituted. R1 and R2 are independently a C1-C4 straight chained or branched alkyl group. Also disclosed is a method of incr

Carbazolyl-substituted ethanolamines as selective beta -3 agonists

PCT No. PCT/US97/15230 Sec. 371 Date May 4, 1998 Sec. 102(e) Date May 4, 1998 PCT Filed Aug. 28, 1997 PCT Pub. No. WO98/09625 PCT Pub. Date Mar. 12, 1998Disclosed herein are selective beta 3 adrenergic agonists represented by the following structural formula: The variables in the structural formula shown above are defined in the specification. Also disclosed are methods of using these compounds for agonizing the beta 3 adrenergic receptor in patients in need of such treatment, for example, patients in need of treatment for obesity or Type II diabetes.